EMA CHMP gives positive opinion on daratumumab use in smouldering myeloma patients with high risk of developing myelomaAccess, MyelomaJune 27, 2025
EMA CHMP gives positive opinion on belantamab mafodotin combinations for relapsed/refractory myeloma patientsSin categorÃaMay 28, 2025
AL amyloidosis phase III clinical trial of birtamimab fails to meet primary endpointAL amyloidosisMay 26, 2025
European Commission approves linvoseltamab for the treatment of relapsed and refractory myelomaAccess, MyelomaApril 29, 2025
